What's also interesting to me is why isn't anyone talking about the already established short term impact. Yes, we all hope and pray for reversing AD and a magic cure. But a drug doesn't need to be that, for it to sell. It just needs to help some % of patients in a valuable, some of the time and do more good then harm.
It seems like at the very least it's an established fact that a dose of Bryostatin has an immediate effect of taking an advanced AD patient who is effectively in a non-responsive vegetative state and awakening them to a degree where they can have a conversation with their loved ones. Perhaps a last few weeks of conversations. Isn't that in itself valuable enough for this drug to be useful?
Yes, it seems like it's really much more then that. It seems based on the science that AD is actually reversed. But if the question is whether Bryostatin and NTRP have value, isn't there value just in the immediate proven impact?
Market Data 
Markets 
AI
